Processa Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Processa Pharmaceuticals Inc cash flow-to-debt ratio. Processa Pharmaceuticals Inc (PCSA) has a Cash Flow-to-Debt Ratio of -1.81x as of March 2026, meaning its operating cash flow of $-3.59 Million could theoretically repay -2% of its total liabilities ($1.98 Million) in one year. Check PCSA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Processa Pharmaceuticals Inc (2011–2025)
Cash flow-to-debt ratio of Processa Pharmaceuticals Inc from 2011 to 2025. Historical debt coverage capacity for Processa Pharmaceuticals Inc across 15 annual periods. Check PCSA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Processa Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2011–2025)
Processa Pharmaceuticals Inc cash flow-to-debt ratio by year from 2011 to 2025. Year-by-year debt coverage analysis for Processa Pharmaceuticals Inc. For the full cash flow conversion analysis, see PCSA cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.09x | $-11.39 Million | $2.24 Million | ▲ +30.6% |
| 2024 | -7.33x | $-11.25 Million | $1.53 Million | ▲ +27.5% |
| 2023 | -10.11x | $-8.06 Million | $797.48K | ▼ -21.0% |
| 2022 | -8.36x | $-9.61 Million | $1.15 Million | ▲ +6.2% |
| 2021 | -8.91x | $-8.72 Million | $978.40K | ▼ -544.8% |
| 2020 | -1.38x | $-3.14 Million | $2.27 Million | ▼ -44.2% |
| 2019 | -0.96x | $-2.75 Million | $2.87 Million | ▲ +9.2% |
| 2018 | -1.06x | $-3.71 Million | $3.51 Million | ▼ -66.4% |
| 2017 | -0.63x | $-1.65 Million | $2.61 Million | ▼ -51.5% |
| 2016 | -0.42x | $-871.91K | $2.08 Million | ▲ +0.0% |
| 2015 | -0.42x | $-871.91K | $2.08 Million | ▲ +79.3% |
| 2014 | -2.02x | $-2.70 Million | $1.33 Million | ▼ -0.8% |
| 2013 | -2.00x | $-2.54 Million | $1.27 Million | ▼ -40.4% |
| 2012 | -1.43x | $-1.89 Million | $1.32 Million | ▼ -408.7% |
| 2011 | -0.28x | $-710.00K | $2.53 Million | — |